Home Cart Sign in  
Chemical Structure| 1029044-16-3 Chemical Structure| 1029044-16-3

Structure of Pexidartinib
CAS No.: 1029044-16-3

Chemical Structure| 1029044-16-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive inhibitor of colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit, with IC50 values of 20 nM and 10 nM, respectively. It exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases, induces cell apoptosis, and has anti-tumor activity.

Synonyms: PLX-3397

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pexidartinib

CAS No. :1029044-16-3
Formula : C20H15ClF3N5
M.W : 417.81
SMILES Code : FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F
Synonyms :
PLX-3397
MDL No. :MFCD28900745
InChI Key :JGWRKYUXBBNENE-UHFFFAOYSA-N
Pubchem ID :25151352

Safety of Pexidartinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pexidartinib

RTK

Isoform Comparison

Biological Activity

Target
  • c-Kit

    Kit, IC50:10 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
CD14+ mononuclear macrophages 200 nM 3 days Blocking the CSF1 receptor reduced CD163+M2 macrophage differentiation induced by EBV-infected tumor supernatant PMC11184188
MOLM-14 51 nM 48 h To evaluate the inhibitory effect of Pexidartinib on MOLM-14 cells, results showed that cell viability decreased with increasing drug concentration. PMC8033742
MV4-11 37 nM 48 h To evaluate the inhibitory effect of Pexidartinib on MV4-11 cells, results showed that cell viability decreased with increasing drug concentration. PMC8033742
RAW264.7 macrophages 5 μg/mL 24 h To evaluate the effect of Pexidartinib on macrophage polarization, the results showed that Pexidartinib could induce macrophage polarization to the M1 phenotype. PMC9039063
HUVECs 30 nM 48 h To evaluate the effect of Pexidartinib on HUVECs cell viability, the results showed that Pexidartinib significantly reduced the cell viability of HUVECs. PMC9971365

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NCG mice C666-1-A11-LMP2A subcutaneous xenograft model Intraperitoneal injection 20 mg/kg Twice a week, starting from the time of immune cell injection MMP9 inhibitors restored TCR-T cell function suppressed by M2 macrophages, inhibiting the growth of EBV-infected tumors PMC11184188
mice 4T1 tumor model intratumoral injection 4 mg/mL injections on day 1, 3, and 5, lasting for 15 days To evaluate the role of Pexidartinib in tumor immunotherapy, the results showed that Pexidartinib could significantly inhibit tumor growth and induce macrophage polarization to the M1 phenotype. PMC9039063
Mice Acute ventilator-induced lung injury model Oral 600 mg/kg Daily, for two weeks To study the effect of Pexidartinib in depleting microglia by inhibiting CSF1R receptor in a mouse model and evaluate its impact on neuronal injury and delirium-like behaviors. Results showed that Pexidartinib significantly reduced microglia numbers and exacerbated neuronal injury and delirium-like behaviors. PMC11495074
Mice P21 wildtype C57Bl/6 mice Oral 290 mg/kg 7 days continuously Eliminate microglia PMC5404890
Mice FVB/N mice Oral gavage 45 mg/kg Once daily for 2 weeks To deplete macrophages by inhibiting CSF1R, results showed a significant reduction in macrophage counts in the mammary gland and increased levels of hyaluronan and collagen in the adipose stroma. PMC7297528
Mice Acute ventilator-induced lung injury model Oral 600 mg/kg Daily for two weeks To evaluate the effect of microglia depletion on VILI-induced neuronal injury and delirium-like behaviors. Results showed that PEXI-treated mice exhibited more severe neuronal injury and delirium-like behaviors after VILI. PMC11495074

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04488822 Tenosynovial Giant Cell Tumor PHASE3 ACTIVE_NOT_RECRUITING 2026-02-28 Beijing Ji Shui Tan Hospital, ... More >>Beijing, China|Peking University Cancer Hospital, Beijing, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai General Hospital, Shanghai, China|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan Less <<
NCT04703322 Tenosynovial Giant Cell Tumor PHASE2 ACTIVE_NOT_RECRUITING 2026-05-31 Nagoya University Hospital, Ai... More >>chi, 466-8560, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan Less <<
NCT04223635 Moderate Hepatic Impairment EARLY_PHASE1 COMPLETED 2020-10-02 Clinical Pharmacology of Miami... More >>, LLC., Miami, Florida, 33014-3616, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT02734433 Advanced Solid Tumors PHASE1 COMPLETED 2021-05-28 Taipei, Taiwan
NCT04526704 Tenosynovial Giant Cell Tumor PHASE4 COMPLETED 2023-07-07 Honor Health, Scottsdale, Ariz... More >>ona, 85258, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Washington University, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3000, Australia|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, H-1062, Hungary|Rizzoli-Istituto Ortopedico Rizzoli, Bologna, 40136, Italy|Fondazione IRCC Istituto Nazionale dei Tumori, Milano, 20133, Italy|Leiden University Medical Center (LUMC), Leiden, 2333 ZA, Netherlands|Hospital Sant Pau, Barcelona, 08041, Spain|Hospital Virgen del Rocio, Sevilla, 41013, Spain|National Taiwan University Hospital, Taipei, Taiwan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.97mL

2.39mL

1.20mL

23.93mL

4.79mL

2.39mL

References

 

Historical Records

Categories